Aclaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 06, 2023 at 12:31 pm
Share
Aclaris Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 9.28 million compared to USD 19.02 million a year ago. Net loss was USD 29.26 million compared to USD 19.95 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 0.3 a year ago.
For the nine months, revenue was USD 13.68 million compared to USD 22 million a year ago. Net loss was USD 86.99 million compared to USD 59.27 million a year ago. Basic loss per share from continuing operations was USD 1.25 compared to USD 0.92 a year ago.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
ACLARIS THERAPEUTICS, INC. 
